NCT03760315

Brief Summary

mNGS is popular in research and recently it has been used clinically to detect microbes in the blood or other secretion in infected patients for quicker ,broad and accurate detection of microbes. In ICU ,patients are critically ill and need quicker and accurate antibiotics use to stop the pathologic process. The purpose of this study was to determine whether the positive detection rate of pathogens in patients with sepsis by metagenomic full-targeted detection technology was higher than that in blood culture, and to determine whether the pathogens found in patients with sepsis by metagenomic full-targeted detection technology were important for clinical development. Anti-infective regimens can help.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
210

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 28, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 30, 2018

Completed
3.3 years until next milestone

Study Start

First participant enrolled

April 1, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

August 5, 2022

Status Verified

August 1, 2022

Enrollment Period

9 months

First QC Date

November 28, 2018

Last Update Submit

August 2, 2022

Conditions

Keywords

next- generation sequencing; blood culture;IDSeqTM Ultra

Outcome Measures

Primary Outcomes (1)

  • difference of positive rate between mNGS and Culture

    The difference between the positive rate of mNGS and the positive rate of blood culture.

    28 day

Secondary Outcomes (5)

  • The difference between the positive rate of metagenomic full capture technology and the Category of Clinical Impact

    28 day

  • Change of SOFA

    7 day

  • Mortality

    During hospitalization

  • Length of stay

    During hospitalization

  • Anti-infective treatment adjustment

    28 day

Other Outcomes (2)

  • pathogen

    28 day

  • secondary infection

    28 day

Study Arms (1)

Sepsis

All enrolled patients

Diagnostic Test: blood mNGS (IDSeqTM Ultra); blood Culture

Interventions

take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.

Sepsis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with sepsis and suspected bloodstream infection

You may qualify if:

  • Age \> 18years admit to ICU Meet the Sepsis 3.0 diagnostic criteria and suspected bloodstream infection, and the diagnosis of Sepsis ≤ 24 hours; Estimated ICU stay ≥ 24 hours; Informed consent;

You may not qualify if:

  • Severe organ dysfunction, expected death within 72 hours; Receive palliative care; Refuse to participate;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing Zhong-Da Hospital

Nanjing, Jiangsu, 210009, China

RECRUITING

Related Publications (1)

  • Sun Q, Teng R, Shi Q, Liu Y, Cai X, Yang B, Cao Q, Shu C, Mei X, Zeng W, Hu B, Zhang J, Qiu H, Liu L. Clinical implement of Probe-Capture Metagenomics in sepsis patients: A multicentre and prospective study. Clin Transl Med. 2025 Apr;15(4):e70297. doi: 10.1002/ctm2.70297.

Biospecimen

Retention: SAMPLES WITH DNA

DNA extracted from blood

MeSH Terms

Conditions

Sepsis

Interventions

Blood Culture

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Microbiological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • Haibo Qiu, MD

    Southeast University, China

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

November 28, 2018

First Posted

November 30, 2018

Study Start

April 1, 2022

Primary Completion

December 30, 2022

Study Completion

December 30, 2022

Last Updated

August 5, 2022

Record last verified: 2022-08

Locations